Wednesday, August 10, 2022
1:00 PM-2:00 PM ET
Melissa Badowski, PharmD, MPH, FCCP, BCIDP, BCPS
Clinical Associate Professor
College of Pharmacy - Pharmacy Practice
University of Illinois, Chicago
Jennifer Cocohoba, PharmD, MAS
Vice Chair of Faculty Development
McKesson Professor of Pharmaceutical Technology
Department of Clinical Pharmacy
Clinical pharmacist for the UCSF Women's HIV Program
University of California, San Francisco
San Francisco, California
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is in collaboration with HealthHIV.
This activity is supported by an educational grant from Gilead Sciences, Inc.
The educational design of this activity addresses the needs of clinical, specialty, and managed care pharmacists and pharmacy benefits managers involved in the care of patients with HIV infection.
The HIV treatment landscape has expanded significantly in recent years. There are now multiple available oral 2-drug regimens and 1 long-acting injectable, with the potential for more long-acting injectables in the future. It is important for pharmacists to understand the risks, benefits, and selection criteria of both oral and injectable 2-drug regimens, particularly as they educate patients about appropriate use and any potential adverse events or drug-drug interactions. Long-acting injectables are accompanied by infrastructure changes and requirements for further clinician education. Pharmacists play an important role in the multidisciplinary team and require updates about newer treatment options in HIV. Dr. Melissa Badowski and Dr. Jennifer Cocohoba discuss recently available and emerging antiretroviral therapy (ART) and the role pharmacists may play in patient management.
Upon completion of this activity, the participant should be better able to:
- Describe pharmacologic characteristics that support the efficacy and viability of 2-drug oral and long-acting injectable ART regimens
- Evaluate risks and benefits of 2-drug regimens to individualize for patients
- Review risks, benefits, and requirements for use of long-acting injectables to manage HIV
- Welcome and Faculty Introductions
- Persisting Challenges and Potential Solutions in HIV—An Overview
- 2-Drug Regimens (2-DR): When and for Whom Are They Appropriate
- Long-Acting Injectables: The Future of HIV Treatment?
- Concluding Comments and Faculty Q&A Session
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
Global Education Group designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-22-086-L02-P)
This is a knowledge-based activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.
Instructions to Recieve Credit
In order to receive credit for this activity, the participant must review the activity as well as successfully complete the posttest, by achieving a score of 70% or higher, and evaluation form.
Pharmacist learners: please check CPE monitor for credit within 30 days of the activity.
There is no fee for this educational activity.
Disclosures of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Melissa Badowski, PharmD, MPH, FCCP, BCIDP, BCPS - Nothing to disclose
Jennifer Cocohoba, PharmD, MAS - Contracted research: ViiV Healthcare (provided directly to institution); Walgreens Company (provided directly to institution)
PharmD Fellowship Program: Genentech, Inc., Janssen Pharmaceuticals, Inc.
The planners and managers have the following relevant financial relationships with ineligible companies:
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.